Company / Capital Expenditures
RIGEL PHARMACEUTICALS INC Capital Expenditures History
FY2016-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$450.0K
FY2022
5-year range
$450.0K / $627.0K
FY2018-FY2022
Trend
-28.2%
vs FY2021
Sector context
#142 of 194
Health Care
What the data says
At $450,000, RIGEL PHARMACEUTICALS INC's capital expenditures ranks #142 of 194 in the Health Care sector. Capital Expenditures has declined for 3 consecutive years, from $1M in FY2019 to $450,000 in FY2022.
Based on SEC 10-K filings.
$450,000 in FY2022 with a 5-year CAGR of +22.4%.
Declined from $1M to $450,000 over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -32.4%
- 5-Year CAGR
- +22.4%
- 10-Year CAGR
- -
Sector benchmark
#142 of 194 in Health CareTop 73% of 194This company $450.0K Sector average $117.5M
▼
-99.6% below sector average
Key checks
Key Insights
- RIGEL PHARMACEUTICALS INC's capital expenditures has declined for 3 consecutive years.
- 5-year CAGR of +22.4%, indicating consistent growth.
- In FY2022, capital expenditures decreased 28.2% year-over-year.
- Ranks #142 out of 194 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 1.19 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | $450.0K | -28.2% |
| FY2021 | $627.0K | -50.3% |
| FY2020 | $1.3M | -13.3% |
| FY2019 | $1.5M | +81.0% |
| FY2018 | $804.0K | +390.2% |
| FY2017 | $164.0K | -79.6% |
| FY2016 | $804.0K | +47.3% |
As of FY2022 · SEC 10-K · Updated Jun 30, 2026